Stocks: Overview  

Sunday, May 19, 2013 4:50:48 AM EDT
Show Me
|

 

CytRx CorpCYTR
Alcoa IncAA
Touchstone Small Cap Growth Fund Class YMXAIX
Pep Boys-Manny Moe and JackPBY
LinkedIn CorpLNKD
General Electric CoGE
MFS Lifetime 2010 Fund Class IMFSIX
Novartis AGNVS
Viacom IncVIA
E*TRADE Financial CorpETFC

CytRx CorpNASDAQ:CYTR    

Health Care : BiotechnologySmall Cap Blend
$2.45 
 0.02 (0.81%)        
Bid
--
Ask
--
B/A Size
--
High
2.48
Low
2.35
Volume
88,772 (Light)
Change company  Symbol lookup
As of May 17, 2013 4:00pm ET
  • Summary
  • News
  • Charts
  • Earnings
  • Fundamentals
  • Valuation
  • Calendar
  • Analyst Reports
  • SEC Filings

2.47

74.8M


2.48

30.5M


2.35 - 2.48

-0.89


152.7K

--


4:00p ET 05/17/13

No Regular Dividends


5.1K

--


Low
High

1.2


54.09%

9.84


85.4%

3.35


64.3%

Historical Quotes & Splits
 

Current|1mo|3mo|6mo|1yr
DJIA
S&P 500
NASDAQ
SMA(50)
View Advanced Chart
  • News
  • Industry Position
  • Company Profile

May 9, 2013

8:30a
CytRx Reports 2013 First Quarter Financial Results   (Business Wire)

May 8, 2013

8:30a
CytRx Provides Update on Clinical Programs   (Business Wire)

May 6, 2013

8:30a
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma   (Business Wire)

April 23, 2013

8:30a
CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma   (Business Wire)

March 12, 2013

8:30a
CytRx to Present at the 25th Annual ROTH Conference   (Business Wire)

March 11, 2013

8:30a
CytRx Reports 2012 Financial Results   (Business Wire)

March 1, 2013

8:30a
CytRx to Present at the Cowen & Company 33rd Annual Health Care Conference   (Business Wire)

February 28, 2013

8:30a
CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer   (Business Wire)
Go to All Current & Historical News
Events
05/09/2013
Q1 2013 CytRx Corp Earnings Release - Estimate: $-0.23
03/11/2013
Q4 2012 CytRx Corp Earnings Release - Estimate: $0.25
11/09/2012
Q3 2012 CytRx Corp Earnings Release - Estimate: $0.07
08/09/2012
Q2 2012 CytRx Corp Earnings Release - Estimate: $-0.63
More Calendar Events
Market data accompanied by       is delayed by at least 15 minutes for NASDAQ, AMEX, NYSE and Options. Duration of the delay for other exchanges vary.
THOMSON REUTERS  
Market data and information provided by Thomson Reuters; ©  
Thomson Reuters Limited.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Information and news provided by 
, 
Computrade Systems, Inc., 
 , 
,  
, 
and 

Copyright ©2013. All rights reserved.


S&P Capital IQ Research Disclosure /public-4:50:47

3rd Party Research Disclosure /public-4:50:47

Market Data Disclosure